CR10346A - Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3 - Google Patents

Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3

Info

Publication number
CR10346A
CR10346A CR10346A CR10346A CR10346A CR 10346 A CR10346 A CR 10346A CR 10346 A CR10346 A CR 10346A CR 10346 A CR10346 A CR 10346A CR 10346 A CR10346 A CR 10346A
Authority
CR
Costa Rica
Prior art keywords
group
azabiciclo
hexil
dopamine
receivers
Prior art date
Application number
CR10346A
Other languages
English (en)
Inventor
Bertani Barbara
Bonanomi Giorgio
Maria Capelli Anna
Checchia Anna
Di Fabio Romano
Gentile Gabriella
Micheli Fabrizio
Pasquarello Alessandra
Tedesco Giovanna
Terreni Silvia
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607892A external-priority patent/GB0607892D0/en
Priority claimed from GB0700363A external-priority patent/GB0700363D0/en
Priority claimed from GB0703404A external-priority patent/GB0703404D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR10346A publication Critical patent/CR10346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a nuevos compuestos de formula (I) o una sal de los mismos: donde G se selecciona entre un grupo que consiste en: fenilo, un grupo heteroarilo monociclico de 5 o 6 miembros o un grupo heteroarilo biciclico de 8 a 11 miembros; A es un grupo P1 o un grupo P2 donde P1 es y P2 es, p es un numero entero que varia de 0 a 5; R1 es halogeno, hidroxi, ciano, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4, alcanoilo C1-4, y SF5; o corresponde a un grupo R6; Y donde p es un numero entero que varia de 2 a 5, pudiendo ser os R1 iguales o diferentes.
CR10346A 2006-04-03 2008-10-07 Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3 CR10346A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0607892A GB0607892D0 (en) 2006-04-03 2006-04-03 Novel compounds
GB0700363A GB0700363D0 (en) 2007-01-09 2007-01-09 Novel compounds
GB0703404A GB0703404D0 (en) 2007-02-21 2007-02-21 Novel compounds

Publications (1)

Publication Number Publication Date
CR10346A true CR10346A (es) 2008-10-29

Family

ID=38283980

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10346A CR10346A (es) 2006-04-03 2008-10-07 Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3

Country Status (17)

Country Link
US (1) US7727988B2 (es)
EP (1) EP2007750B1 (es)
JP (1) JP5189074B2 (es)
KR (1) KR20080109063A (es)
AR (1) AR060237A1 (es)
AU (1) AU2007233715A1 (es)
BR (1) BRPI0709660A2 (es)
CA (1) CA2648087A1 (es)
CR (1) CR10346A (es)
EA (1) EA200870404A1 (es)
ES (1) ES2434337T3 (es)
IL (1) IL194385A0 (es)
MA (1) MA30355B1 (es)
MX (1) MX2008012875A (es)
PE (1) PE20071152A1 (es)
TW (1) TW200815404A (es)
WO (1) WO2007113232A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2060570E (pt) * 2004-02-23 2012-05-07 Glaxo Group Ltd Derivados de azabiciclo(3.1.0)-hexano úteis como moduladores dos receptores d3 da dopamina
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
ATE484502T1 (de) * 2005-06-14 2010-10-15 Glaxo Group Ltd Neue verbindungen
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
EP1919908B1 (en) * 2005-08-22 2010-11-10 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
GB0517175D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US8163927B2 (en) * 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors
WO2007113260A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
GB0719235D0 (en) * 2007-10-02 2007-11-14 Glaxo Group Ltd Novel compounds
CN102803224A (zh) 2009-06-26 2012-11-28 万能药生物有限公司 新的氮杂双环己烷类化合物
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
MX2015007921A (es) * 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.
WO2015002754A2 (en) 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
WO2015004534A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
DE4338396A1 (de) 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
PT2060570E (pt) * 2004-02-23 2012-05-07 Glaxo Group Ltd Derivados de azabiciclo(3.1.0)-hexano úteis como moduladores dos receptores d3 da dopamina
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0512099D0 (en) 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
WO2007113260A1 (en) 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
US8163927B2 (en) 2006-04-03 2012-04-24 Glaxo Group Limited Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors

Also Published As

Publication number Publication date
TW200815404A (en) 2008-04-01
MA30355B1 (fr) 2009-04-01
AU2007233715A1 (en) 2007-10-11
WO2007113232A1 (en) 2007-10-11
JP2009532424A (ja) 2009-09-10
JP5189074B2 (ja) 2013-04-24
EA200870404A1 (ru) 2009-04-28
CA2648087A1 (en) 2007-10-11
KR20080109063A (ko) 2008-12-16
MX2008012875A (es) 2008-10-13
EP2007750B1 (en) 2013-08-21
IL194385A0 (en) 2009-08-03
AR060237A1 (es) 2008-06-04
US7727988B2 (en) 2010-06-01
EP2007750A1 (en) 2008-12-31
US20070249642A1 (en) 2007-10-25
ES2434337T3 (es) 2013-12-16
BRPI0709660A2 (pt) 2011-07-19
PE20071152A1 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
CR10346A (es) Derivados de azabiciclo[3.1.0]hexil como modulares de los receptores de dopamina d3
UY33842A (es) ?pesticidas mesoiónicos?.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
RS53348B (en) PROCEDURE FOR THE PREPARATION OF 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES
AR061134A1 (es) Derivados de tioxantina
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
UY29388A1 (es) Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica.
AR040546A1 (es) Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
MX337714B (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
RS54183B1 (en) PIRAZOLE DERIVATIVES
CO6501175A2 (es) Derivados de benzotiazinas, su preparación y aplicación como fármacos
RS54595B1 (en) 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
RS53389B (en) PHARMACEUTICAL UNITS
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
AR062082A1 (es) Derivados de piridazina con actividad microbicida
CR20110360A (es) Derivados de 2-piridin-2-il-pirazol-3-(2h)-ona, su preparacion y su aplicacion en terapeutica
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR071954A1 (es) Derivados de 3-oxo-isoindol-1-carboxamida utiles en terapia para el dolor y una composicion farmaceutica que los comprende.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)